Adding Ticagrelor to Aspirin After Clot-Busting Therapy Improves Stroke Recovery — Tiantan Hospital TAPIS Trial Published in The Lancet

Adding Ticagrelor to Aspirin After Clot-Busting Therapy Improves Stroke Recovery — Tiantan Hospital TAPIS Trial Published in The Lancet

omuat.com | June 20, 2026

When a stroke patient receives intravenous thrombolysis — the clot-dissolving drug that is the gold standard for acute ischemic stroke treatment — the race against time does not end when the clot dissolves. Within hours, the artery can re-occlude, and the patient’s recovery stalls. Now a landmark trial from Beijing Tiantan Hospital, published in The Lancet (PMID: 42114550), has shown that starting dual antiplatelet therapy (ticagrelor plus aspirin) within hours after thrombolysis significantly improves functional outcomes at 90 days — without increasing the risk of the most feared complication, symptomatic intracranial hemorrhage. The TAPIS trial is the first large randomized controlled trial to demonstrate that early intensive antiplatelet therapy after intravenous thrombolysis is both safe and effective, and it may change stroke treatment protocols worldwide.

Table of Contents

• Acute Ischemic Stroke: The Time-Critical Emergency
• The Thrombolysis Paradox: Clot Dissolved, But Not Safe
• The TAPIS Trial: Design
• Results: Better Recovery Without More Bleeding
• Why Ticagrelor: The Pharmacological Advantage
• How This Changes Stroke Treatment
• Tiantan Hospital: China’s National Stroke Center
• Global Implications and Next Steps
• Sources

Acute Ischemic Stroke: The Time-Critical Emergency

Acute ischemic stroke — caused by a blood clot blocking an artery supplying the brain — is the second leading cause of death and the leading cause of disability worldwide. Every year, approximately 12 million people suffer an ischemic stroke, and 6.7 million die from it. In China alone, stroke is the leading cause of death, with approximately 3.9 million new stroke events annually.

The Treatment Window

The only approved pharmacological treatment for acute ischemic stroke is intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator, rt-PA) or, more recently, tenecteplase, administered within 4.5 hours of symptom onset. This therapy dissolves the obstructing clot and restores blood flow to the ischemic brain. The earlier it is given, the more effective it is — the “time is brain” concept reflects that approximately 1.9 million neurons die per minute during an untreated ischemic stroke.

The Outcome Gap

Despite timely thrombolysis, outcomes remain disappointingly poor for many patients. Only approximately 30-35% of patients who receive intravenous thrombolysis achieve excellent functional outcomes (modified Rankin Scale score of 0-1, meaning no significant disability) at 90 days. The remaining 65-70% are left with varying degrees of disability, dependence, or death. This outcome gap reflects several factors, but one of the most important is early re-occlusion — the dissolved clot reforms, or new thrombi develop at the site of the original occlusion, cutting off blood flow again.

The Thrombolysis Paradox: Clot Dissolved, But Not Safe

After intravenous thrombolysis, the damaged endothelium at the site of the dissolved clot is highly thrombogenic — it exposes subendothelial collagen and tissue factor that activate platelets and the coagulation cascade. Platelet activation is the primary driver of early re-occlusion, making antiplatelet therapy a logical intervention. But here lies the paradox: the same thrombolysis that dissolves the clot also creates a vulnerable state in the brain where any additional antithrombotic effect could cause catastrophic intracranial hemorrhage.

The Safety Fear

The fear of hemorrhagic transformation — bleeding into the ischemic brain tissue — has historically limited antiplatelet therapy after thrombolysis. Current guidelines recommend only single-agent aspirin (160-300 mg) starting 24 hours after thrombolysis, after a follow-up CT scan excludes hemorrhage. Starting dual antiplatelet therapy earlier has been considered too risky because:

• Thrombolysis degrades the blood-brain barrier: Alteplase activates matrix metalloproteinases that degrade the basal lamina of cerebral vessels, making them more permeable and more likely to bleed
• Ischemic tissue is fragile: The ischemic penumbra — the partially damaged tissue surrounding the core infarct — has compromised vascular integrity and is susceptible to hemorrhagic transformation if antithrombotic therapy is intensified
• Historical precedent: The IST-3 trial and other studies showed that adding antithrombotic agents to thrombolysis increased hemorrhage risk, creating a cautionary legacy

The result has been a treatment gap: patients receive clot-dissolving therapy, then wait 24 hours with only suboptimal antiplatelet protection while the risk of re-occlusion is highest — during the first hours after thrombolysis.

The TAPIS Trial: Design

The TAPIS (Ticagrelor with Aspirin Dual Antiplatelet Therapy Combined with Intravenous Thrombolysis in Patients with Ischaemic Stroke in China) trial was designed to answer the fundamental question: is early dual antiplatelet therapy after intravenous thrombolysis safe and effective?

Trial Methodology

TAPIS was a multicenter, double-blind, randomized, placebo-controlled trial conducted at 60 stroke centers across China. Key design elements:

• Patients: 1,382 adults with acute ischemic stroke who received intravenous alteplase within 4.5 hours of symptom onset
• Randomization: Patients were randomized 1:1 to receive either ticagrelor (180 mg loading dose, then 90 mg twice daily) plus aspirin (300 mg loading, then 100 mg daily), or matching placebo plus aspirin (same aspirin regimen)
• Timing: Antiplatelet therapy was initiated within hours after thrombolysis — not the traditional 24-hour delay
• Blinding: Double-blind design with matching placebo, ensuring that outcome assessment was not influenced by knowledge of treatment assignment
• Primary endpoint: Excellent functional outcome at 90 days, defined as modified Rankin Scale (mRS) score of 0-1 (no symptoms to no significant disability despite symptoms)
• Key safety endpoint: Symptomatic intracranial hemorrhage (sICH) within 72 hours, defined as any hemorrhage associated with neurological deterioration

Why Ticagrelor Over Clopidogrel

The choice of ticagrelor rather than clopidogrel for dual antiplatelet therapy was deliberate and important. Clopidogrel is a prodrug that requires hepatic activation via CYP2C19 — a pathway with significant genetic variability. Approximately 30% of Chinese patients carry loss-of-function CYP2C19 variants that make clopidogrel substantially less effective (clopidogrel resistance). Ticagrelor, by contrast, is a direct-acting P2Y12 inhibitor that does not require metabolic activation, providing rapid, potent, and consistent platelet inhibition regardless of CYP2C19 genotype — a critical advantage in a population with high rates of clopidogrel resistance.

Results: Better Recovery Without More Bleeding

The TAPIS trial produced a clear and clinically meaningful result: early dual antiplatelet therapy after thrombolysis improved outcomes without increasing the most feared complication.

Efficacy Results

• Excellent functional outcome (mRS 0-1) at 90 days: 68.7% in the ticagrelor-aspirin group vs 62.0% in the aspirin-alone group (relative risk 1.11, p=0.0089) — a statistically significant and clinically meaningful improvement
• Functional improvement across the full mRS scale: Ordinal analysis (shift analysis) of the full mRS distribution showed a significant favorable shift toward better outcomes with ticagrelor-aspirin (p=0.0042)
• Recurrent ischemic events: The ticagrelor-aspirin group had fewer recurrent ischemic strokes within 90 days compared to the aspirin-alone group, consistent with the antiplatelet mechanism preventing re-occlusion

Safety Results

• Symptomatic intracranial hemorrhage (sICH): No significant difference between the ticagrelor-aspirin group and the aspirin-alone group — the critical safety endpoint was met. Adding ticagrelor did not increase the rate of the most dangerous bleeding complication
• Major extracranial bleeding: A small increase in minor bleeding events was observed in the ticagrelor group (consistent with the known bleeding profile of P2Y12 inhibitors), but no significant increase in major or life-threatening extracranial hemorrhage

The combination of improved efficacy with maintained safety is the ideal result for an acute stroke therapy — and it addresses the central concern that had prevented early dual antiplatelet therapy from being adopted after thrombolysis.

Why Ticagrelor: The Pharmacological Advantage

The success of ticagrelor in TAPIS reflects specific pharmacological properties that make it well-suited for the acute stroke setting.

Rapid Onset and Potent Inhibition

Ticagrelor achieves near-maximal platelet inhibition within 30 minutes of a 180 mg loading dose — far faster than clopidogrel, which requires 2-6 hours to reach adequate inhibition even in good metabolizers. In acute stroke, where the risk of re-occlusion is highest in the first hours after thrombolysis, this rapid onset is critical.

Reversible Binding: A Safety Advantage

Unlike clopidogrel (which irreversibly binds to the P2Y12 receptor for the lifetime of the platelet), ticagrelor binds reversibly. Platelet function begins to recover within 24-72 hours after ticagrelor discontinuation, compared to 5-7 days for clopidogrel. This reversibility provides a safety margin — if a patient develops bleeding that requires surgery or intervention, the antiplatelet effect can be reversed more quickly.

CYP2C19 Independence

The CYP2C19-independent mechanism of ticagrelor is particularly important in the Chinese population, where loss-of-function CYP2C19 alleles (particularly *2 and *3) are carried by approximately 30% of individuals. In the CHANCE trial (also from Tiantan Hospital), clopidogrel-aspirin dual therapy benefited stroke patients overall, but patients with CYP2C19 loss-of-function variants derived significantly less benefit. TAPIS, by using ticagrelor, bypasses this pharmacogenomic limitation entirely.

How This Changes Stroke Treatment

The TAPIS trial has the potential to change clinical practice in several specific ways.

Eliminating the 24-Hour Delay

Current guidelines recommend waiting 24 hours after thrombolysis before starting antiplatelet therapy (and then only aspirin). TAPIS shows that earlier, more intensive antiplatelet therapy — started within hours of thrombolysis — is both safe and beneficial. This could eliminate the 24-hour treatment gap during which patients are at highest risk of re-occlusion but receive only minimal antithrombotic protection.

From Single to Dual Antiplatelet Therapy

The trial supports a shift from single-agent aspirin to dual antiplatelet therapy (ticagrelor plus aspirin) as the standard post-thrombolysis regimen. This would align post-thrombolysis treatment with the dual antiplatelet approach already used in acute coronary syndromes, where DAPT is the standard of care.

The CYP2C19 Question

The TAPIS results may also influence the choice of P2Y12 inhibitor in stroke. Previous Tiantan-led trials (CHANCE, CHANCE-2) established that clopidogrel-aspirin is effective for minor stroke and TIA, but that CYP2C19 genotype matters — patients with loss-of-function variants should receive ticagrelor instead. TAPIS extends the ticagrelor evidence to the thrombolysis-treated population, and together with CHANCE-2, makes a strong case for ticagrelor as the preferred P2Y12 inhibitor in Chinese (and other East Asian) stroke patients.

Tiantan Hospital: China’s National Stroke Center

Beijing Tiantan Hospital, Capital Medical University, is China’s — and one of the world’s — premier stroke centers. The hospital’s Department of Neurology, where TAPIS was led by principal investigator Dr. Yilong Wang and first author Dr. Anxin Wang, has conducted more large-scale stroke randomized controlled trials than virtually any other center globally.

A Legacy of Stroke Trial Leadership

Tiantan Hospital’s stroke trial program, led by Dr. Yilong Wang and Dr. Yongjun Wang, has produced a remarkable series of practice-changing trials:

• CHANCE (2013): Demonstrated that clopidogrel-aspirin dual therapy reduces stroke recurrence after minor stroke/TIA — a result now incorporated into guidelines worldwide
• CHANCE-2 (2021): Showed that CYP2C19-guided selection of ticagrelor vs clopidogrel improves outcomes in carriers of loss-of-function variants
• OPTION (2025): Evaluated tenecteplase for non-large vessel occlusion stroke
• TNK-PLUS (2026): Tested tenecteplase before endovascular treatment for large vessel occlusion (published in JAMA)
• TAPIS (2026): The current trial, adding ticagrelor to aspirin after intravenous thrombolysis

This sustained trial leadership has made Tiantan Hospital the most influential stroke research center in the world for antiplatelet therapy optimization, and its results have directly shaped stroke treatment guidelines used by neurologists on every continent.

China’s Stroke Research Advantages

China’s ability to conduct large, high-quality stroke trials rapidly reflects several structural advantages:

• High stroke incidence: China has the world’s largest stroke population, enabling rapid recruitment for large trials
• Coordinated stroke center network: The China Stroke Center Alliance (CSCA) links hundreds of hospitals in a collaborative research network, enabling multicenter enrollment
• Streamlined regulatory processes: China’s regulatory framework for investigator-initiated trials in stroke has become increasingly efficient

Global Implications and Next Steps

The TAPIS results are immediately relevant to stroke practice worldwide, but several questions remain.

Generalizability to Non-Chinese Populations

The trial was conducted entirely in China, and the benefit of ticagrelor may be particularly pronounced in East Asian populations due to the high prevalence of CYP2C19 loss-of-function variants. In populations with lower rates of clopidogrel resistance (e.g., European populations), the relative advantage of ticagrelor over clopidogrel may be smaller. International replication trials would be valuable to confirm the benefit across ethnic groups.

Combination with Endovascular Treatment

The TAPIS trial focused on patients who received intravenous thrombolysis alone. An important next question is whether early ticagrelor-aspirin DAPT also benefits patients who undergo endovascular thrombectomy (mechanical clot removal) — a rapidly growing treatment for large vessel occlusion stroke. The BRIDGE-T trial and other ongoing studies are addressing this question.

Optimal Treatment Duration

The TAPIS protocol continued ticagrelor-aspirin DAPT for 90 days. Whether shorter or longer durations of DAPT after thrombolysis produce similar or better risk-benefit profiles remains to be determined.

Sources

• Wang A, et al. “Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised, placebo-controlled trial.” The Lancet, 2026;399(10343). PMID: 42114550
• Wang Y, Wang Y, et al. “Clopidogrel with aspirin in acute minor stroke or transient ischaemic attack (CHANCE).” The New England Journal of Medicine, 2013;369(1):11-19. DOI: 10.1056/NEJMoa1215134
• Wang Y, Meng X, et al. “Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with acute ischaemic stroke or TIA (CHANCE-2).” The New England Journal of Medicine, 2021;385(25):2335-2346. DOI: 10.1056/NEJMoa2111749
• Emberson J, Lees KR, et al. “Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.” The Lancet, 2014;384(9958):1929-1935. DOI: 10.1016/S0140-6736(14)60584-5
• Powers WJ, Rabinstein AA, et al. “Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines.” Stroke, 2019;50(12):e344-e418. DOI: 10.1161/STR.0000000000000211
• Jia B, Jing J, et al. “CYP2C19 loss-of-function alleles and the risk of clopidogrel-treated patients with minor stroke or TIA: a pharmacogenetic analysis of the CHANCE trial.” The Lancet Neurology, 2023;22(3):215-224. DOI: 10.1016/S1474-4422(23)00023-4